Nottingham CRO bolsters pharmacology expertise with appointment of Chief Scientific Officer

Nottingham-based Contract Research Organisation (CRO) Cellomatics Biosciences has announced the appointment of Professor David Lambert, FRCA and FFPMRCA as Chief Scientific Officer (CSO).

Based in Nottingham, Cellomatics is a specialist preclinical CRO with expertise in five main therapeutic areas: oncology, immuno-oncology, immunology, inflammation and respiratory. Founded in 2015, Cellomatics has since positioned itself as the CRO of choice for its growing global client base seeking expert support with the development of bespoke bioassays.

David will retain a part-time contract at the University of Leicester as Professor of Anaesthetic Pharmacology and Deputy Head of the Cardiovascular Sciences Department. David is a Fellow of the British Pharmacological Society and has a wealth of knowledge and expertise that will help to develop a pharmacology specialism at Cellomatics. His experience in clinical departments will be of additional value to Cellomatics.

The CSO role represents a natural progression for David, having previously worked with Cellomatics as a scientific advisor. He will be involved in all aspects of Cellomatics’ work, using his 35 years of research experience to assist the team in drafting proposals and generating data and conclusions for client projects, and his specialist pharmacology expertise to inform experiments and identify solutions to bioscience related questions.

Speaking about his new role as CSO, David says: “I have always toyed with the idea of working in industry but have never had a big enough draw before. That all changed when I began working with Cellomatics – a fast-growing CRO with exciting growth potential. I’m looking forward to applying my expertise to support the company’s continued growth and make a real difference, both within the team and for clients.”

After working with David for a number of years, Cellomatics’ CEO Dr Shailendra Singh is keen to continue the partnership, as he explains: “David is a highly valued and trusted advisor to Cellomatics, and we are delighted to welcome him to the team. His extensive pharmacology expertise, knowledge and insights will be integral to our future growth as we set out to develop a pharmacology specialism in-house for the benefit of our clients.”

For more information, visit: www.cellomaticsbio.com